SIT-011 / Sitryx, Eli Lilly - LARVOL DELTA

Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases (GlobeNewswire) - "Sitryx Therapeutics...announces that Eli Lilly & Company (Lilly) has exercised its option to progress SIT-011. Lilly will now lead further development and commercialisation of the Phase 1 ready immunometabolism-targeting therapy. Under the terms of the exclusive global licensing and research collaboration agreement established by the companies in March 2020, exercise of this option triggers an undisclosed milestone payment to Sitryx and the Company will be eligible to receive additional development, regulatory and commercial milestones in addition to tiered royalties."

Licensing / partnership • Immunology